SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trillium Therapeutics
TRIL 20.36+2.0%2:56 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bladerunner17 who wrote (178)5/15/2018 4:51:16 PM
From: Biomaven  Read Replies (1) of 294
 
I have bought a little more over the last few weeks. Breaking the T-cell group into two subgroups is a positive, as well as the recent change in their trial to no longer exclude "not a candidate for other curative treatment" patients - it's now truly 2nd line in PTCL and 3rd line in CTCL.

PTCL is a very big opportunity it it works there, particularly in Asia (25% of NHL patients vs 10-15% in US). No good treatment at all right now, so bar is exceedingly low.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News